Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43


High-Speed Live-Cell Interferometry: A New Method for Quantifying Tumor Drug Resistance and Heterogeneity.

Huang D, Leslie KA, Guest D, Yeshcheulova O, Roy IJ, Piva M, Moriceau G, Zangle TA, Lo RS, Teitell MA, Reed J.

Anal Chem. 2018 Mar 6;90(5):3299-3306. doi: 10.1021/acs.analchem.7b04828. Epub 2018 Feb 13.


Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.

Hong A, Moriceau G, Sun L, Lomeli S, Piva M, Damoiseaux R, Holmen SL, Sharpless NE, Hugo W, Lo RS.

Cancer Discov. 2018 Jan;8(1):74-93. doi: 10.1158/2159-8290.CD-17-0682. Epub 2017 Sep 18.


Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.

Song C, Piva M, Sun L, Hong A, Moriceau G, Kong X, Zhang H, Lomeli S, Qian J, Yu CC, Damoiseaux R, Kelley MC, Dahlman KB, Scumpia PO, Sosman JA, Johnson DB, Ribas A, Hugo W, Lo RS.

Cancer Discov. 2017 Nov;7(11):1248-1265. doi: 10.1158/2159-8290.CD-17-0401. Epub 2017 Sep 1.


JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma.

Titz B, Lomova A, Le A, Hugo W, Kong X, Ten Hoeve J, Friedman M, Shi H, Moriceau G, Song C, Hong A, Atefi M, Li R, Komisopoulou E, Ribas A, Lo RS, Graeber TG.

Cell Discov. 2016 Sep 6;2:16028. doi: 10.1038/celldisc.2016.28. eCollection 2016.


Radiotherapy for gynecologic cancer in nonagenarian patients: a framework for new paradigms.

Méry B, Ndong SM, Guy JB, Assouline A, Falk AT, Valeille A, Trone JC, Rivoirard R, Auberdiac P, Vallard A, Espenel S, Moriceau G, Collard O, Bosacki C, Jacquin JP, de Laroche G, Fournel P, Chargari C, Magné N.

Chin J Cancer. 2016 May 9;35:43. doi: 10.1186/s40880-016-0104-4.


Clinical Impact of Bevacizumab in Patients with Relapsed Glioblastoma: Focus on a Real-Life Monocentric SurVey (SV1 Study).

Rivoirard R, Chargari C, Guy JB, Nuti C, Peoc'h M, Forest F, Falk AT, Garin C, Adjabi A, Hoarau D, Fotso MJ, Langrand Escure J, Moriceau G, Fournel P, Boutet C, Magné N.

Chemotherapy. 2016;61(5):269-74. doi: 10.1159/000443719. Epub 2016 Apr 9.


[Validation of a questionnaire assessing patients' adherence and skill level of management for oral capecitabine treatment].

Baudot A, Oriol M, Tinquaut F, Moine V, Moriceau G, Muron T, Pacaut C, Collard O, Jacquin JP, Saban-Roche L, Bosacki C, Regnier-Denois V, Chauvin F, Bourmaud A.

Bull Cancer. 2016 Mar;103(3):241-51. doi: 10.1016/j.bulcan.2016.01.010. Epub 2016 Feb 23. French.


[Carcinomatous meningitis: The radiation therapist's point of view].

Espenel S, Vallard A, Langrand-Escure J, Ben Mrad M, Méry B, Rivoirard R, Moriceau G, Guy JB, Trone JC, Moncharmont C, Wang G, Diao P, Bernichon É, Chanal É, Fournel P, Magné N.

Cancer Radiother. 2016 Feb;20(1):54-9. doi: 10.1016/j.canrad.2015.09.011. Epub 2016 Feb 8. Review. French.


Translating Clinical Evidence-Based Medicine into the Real World: Single-Center Experience with Cabazitaxel in Metastatic Prostate Cancer Patients.

Moriceau G, Guillot A, Pacaut C, Méry B, Falk AT, Trone JC, Collard O, De Laroche G, Fournel P, Merrouche Y, Magné N.

Chemotherapy. 2016;61(3):127-33. doi: 10.1159/000441379. Epub 2016 Jan 12.


Real-World Outcomes of Combination Chemotherapy with Trabectedin plus Pegylated Liposomal Doxorubicin in Patients with Recurrent Ovarian Cancer: A Single-Center Experience.

Moriceau G, Rivoirard R, Méry B, Vallard A, Pacaut C, Trone JC, Espenel S, Bosacki C, Jacquin JP, Magné N.

Chemotherapy. 2016;61(3):122-6. doi: 10.1159/000441378. Epub 2016 Jan 12.


Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?

Pouessel D, Chevret S, Rolland F, Gravis G, Geoffrois L, Roubaud G, Terrisse S, Boyle H, Chevreau C, Dauba J, Moriceau G, Alexandre I, Deplanque G, Chapelle A, Vauleon E, Colau A, Audenet F, Grellety T, Culine S.

Eur J Cancer. 2016 Feb;54:69-74. doi: 10.1016/j.ejca.2015.11.017. Epub 2015 Dec 25.


Preventing healthcare-associated infections: Residents and attending physicians need better training in advanced isolation precautions.

Moriceau G, Gagneux-Brunon A, Gagnaire J, Mariat C, Lucht F, Berthelot P, Botelho-Nevers E.

Med Mal Infect. 2016 Feb;46(1):14-9. doi: 10.1016/j.medmal.2015.11.001. Epub 2015 Dec 2.


Chemotherapy Regimen in Nonagenarian Cancer Patients: A Bi-Institutional Experience.

Rivoirard R, Chargari C, Kullab S, Trone JC, Langrand-Escure J, Moriceau G, Guy JB, Annede P, Méry B, Moncharmont C, Falk AT, Vedrine L, Merrouche Y, Fournel P, Magné N.

Chemotherapy. 2016;61(2):65-71. doi: 10.1159/000441018. Epub 2015 Nov 10.


Social inequalities and cancer: can the European deprivation index predict patients' difficulties in health care access? a pilot study.

Moriceau G, Bourmaud A, Tinquaut F, Oriol M, Jacquin JP, Fournel P, Magné N, Chauvin F.

Oncotarget. 2016 Jan 5;7(1):1055-65. doi: 10.18632/oncotarget.6274.


What makes real world outcomes in soft tissue sarcomas? A mono-institutional trabectedin experience.

Moriceau G, Vallard A, Méry B, Rivoirard R, Langrand-Escure J, Espenel S, Ben Mrad M, Wang G, Diao P, Fournel P, Collard O, Magné N.

Bull Cancer. 2015 Oct;102(10):814-22. doi: 10.1016/j.bulcan.2015.07.010. Epub 2015 Sep 16.


Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.

Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB, Sosman JA, Ribas A, Lo RS.

Cell. 2015 Sep 10;162(6):1271-85. doi: 10.1016/j.cell.2015.07.061.


Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.

Hernandez-Davies JE, Tran TQ, Reid MA, Rosales KR, Lowman XH, Pan M, Moriceau G, Yang Y, Wu J, Lo RS, Kong M.

J Transl Med. 2015 Jul 3;13:210. doi: 10.1186/s12967-015-0581-2.


Real-World Vinflunine Outcomes in Bladder Cancer in a Single-Institution Study: Moving Beyond Clinical Trials.

Moriceau G, Vallard A, Rivoirard R, Méry B, Espenel S, Langrand-Escure J, Ben Mrad M, Wang G, Diao P, Pacaut C, Guillot A, Collard O, Fournel P, Magné N.

Clin Genitourin Cancer. 2015 Dec;13(6):588-92. doi: 10.1016/j.clgc.2015.05.008. Epub 2015 Jun 6.


The Combination of 80 Years of Age and Metastatic Castration-Resistant Prostate Cancer Remain an Uphill Battle: A Case Report with Cabazitaxel as a Double-Edged Sword.

Méry B, Trone JC, Moriceau G, Falk AT, Guillot A, Pacaut C, Collard O, Magné N.

Chemotherapy. 2014;60(5-6):300-1. doi: 10.1159/000377620. Epub 2015 May 20.


Hypofractionated radiation therapy for treatment of bladder carcinoma in patients aged 90 years and more: A new paradigm to be explored?

Méry B, Falk AT, Assouline A, Trone JC, Guy JB, Rivoirard R, Auberdiac P, Escure JL, Moncharmont C, Moriceau G, Almokhles H, de Laroche G, Pacaut C, Guillot A, Chargari C, Magné N.

Int Urol Nephrol. 2015 Jul;47(7):1129-34. doi: 10.1007/s11255-015-0999-8. Epub 2015 May 17.


[Elderly patients and radiotherapy: A short review].

Vallard A, Guy JB, Espenel S, Langrand-Escure J, Trone JC, Méry B, Moriceau G, Rivoirard R, de Laroche G, Chargari C, Magné N.

Bull Cancer. 2015 Jun;102(6):539-49. doi: 10.1016/j.bulcan.2015.03.001. Epub 2015 Mar 31. Review. French.


[Rare cancers and new radiotherapy techniques].

Espenel S, Trone JC, Vallard A, Guy JB, Moriceau G, Méry B, Langrand-Escure J, Rivoirard R, de Laroche G, Chargari C, Magné N.

Bull Cancer. 2015 Jan;102(1):105-12. doi: 10.1016/j.bulcan.2014.12.001. Epub 2014 Dec 30. French.


Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS.

Cancer Cell. 2015 Feb 9;27(2):240-56. doi: 10.1016/j.ccell.2014.11.018. Epub 2015 Jan 15.


General management of nonagenarian patients: a review of the literature.

Rivoirard R, Chargari C, Trone JC, Falk AT, Guy JB, Eddekaoui H, Lahmar R, Pacaut C, Mery B, Assouline A, Auberdiac P, Moriceau G, Gonthier R, Guillot A, Merrouche Y, Magné N.

Swiss Med Wkly. 2014 Dec 23;144:w14059. doi: 10.4414/smw.2014.14059. eCollection 2014. Review.


[Primary digestive melanomas: is there any consensus?].

Eddekkaoui H, Guy JB, Falk AT, Lahmar R, Trone JC, Bahadoor MR, Kullab S, Collard O, Rivoirard R, Moriceau G, Vignot S, Magné N.

Bull Cancer. 2014 Jun;101(6):637-40. doi: 10.1684/bdc.2014.1948. Review. French.


Feasibility of radiation therapy in patients 90years of age and older: a French multicentre analysis.

Chargari C, Moriceau G, Auberdiac P, Guy JB, Assouline A, Tinquaut F, Falk AT, Eddekkaoui H, Bourmaud A, Coscas Y, Annede P, Rivoirard R, Mery B, Trone JC, Otmezguine Y, Pacaut C, Bauduceau O, Vedrine L, Merrouche Y, Magne N.

Eur J Cancer. 2014 May;50(8):1490-7. doi: 10.1016/j.ejca.2014.02.012. Epub 2014 Mar 7.


Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models.

Gobin B, Moriceau G, Ory B, Charrier C, Brion R, Blanchard F, Redini F, Heymann D.

PLoS One. 2014 Mar 5;9(3):e90795. doi: 10.1371/journal.pone.0090795. eCollection 2014.


Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS.

Cancer Discov. 2014 Jan;4(1):80-93. doi: 10.1158/2159-8290.CD-13-0642. Epub 2013 Nov 21.


A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.

Shi H, Hong A, Kong X, Koya RC, Song C, Moriceau G, Hugo W, Yu CC, Ng C, Chodon T, Scolyer RA, Kefford RF, Ribas A, Long GV, Lo RS.

Cancer Discov. 2014 Jan;4(1):69-79. doi: 10.1158/2159-8290.CD-13-0279. Epub 2013 Nov 21.


Analysis of feasibility and toxicity of radiotherapy in centenarians.

Chargari C, Moriceau G, Auberdiac P, Guy JB, Assouline A, Eddekkaoui H, Annede P, Trone JC, Jacob J, Pacaut C, Bauduceau O, Vedrine L, Magne N.

J Am Geriatr Soc. 2013 Oct;61(10):1833-5. doi: 10.1111/jgs.12471. No abstract available.


Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy.

Pacaut C, Bourmaud A, Rivoirard R, Moriceau G, Guy JB, Collard O, Bosacki C, Jacquin JP, Levy A, Chauleur C, Magné N, Merrouche Y.

Am J Clin Oncol. 2015 Jun;38(3):272-7. doi: 10.1097/COC.0b013e3182979b27.


First assessment of whole-brain radiation therapy combined with pemetrexed-based chemotherapy in non-small-cell lung carcinoma: data on safety and efficacy.

Chargari C, Pacaut C, Le Moulec S, Moriceau G, Moussaid Y, Rivoirard R, Dulou R, Jacob J, Guy JB, Bauduceau O, Ceccaldi B, Védrine L, Fournel P, Magné N.

Anticancer Drugs. 2013 Aug;24(7):736-42. doi: 10.1097/CAD.0b013e328360974d.


Pharmacological blocking of the osteoclastic biocorrosion of surgical stainless steel in vitro.

Lionetto S, Little A, Moriceau G, Heymann D, Decurtins M, Plecko M, Filgueira L, Cadosch D.

J Biomed Mater Res A. 2013 Apr;101(4):991-7. doi: 10.1002/jbm.a.34402. Epub 2012 Sep 10.


MDM4 is a key therapeutic target in cutaneous melanoma.

Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de Lange J, Yip D, Goydos J, Haigh JJ, Haupt Y, Larue L, Jochemsen A, Shi H, Moriceau G, Lo RS, Ghanem G, Shackleton M, Bernal F, Marine JC.

Nat Med. 2012 Aug;18(8):1239-47. doi: 10.1038/nm.2863. Epub 2012 Jul 22.


Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.

Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS.

Cancer Discov. 2012 May;2(5):414-24. doi: 10.1158/2159-8290.CD-12-0022. Epub 2012 Apr 1.


Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.

Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS.

Nat Commun. 2012 Mar 6;3:724. doi: 10.1038/ncomms1727.


RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB.

Nature. 2011 Nov 23;480(7377):387-90. doi: 10.1038/nature10662.


Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth.

Moriceau G, Roelofs AJ, Brion R, Redini F, Ebetion FH, Rogers MJ, Heymann D.

Cancer. 2012 Feb 1;118(3):750-60. doi: 10.1002/cncr.26336. Epub 2011 Jul 12.


Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.

Moriceau G, Ory B, Mitrofan L, Riganti C, Blanchard F, Brion R, Charrier C, Battaglia S, Pilet P, Denis MG, Shultz LD, Mönkkönen J, Rédini F, Heymann D.

Cancer Res. 2010 Dec 15;70(24):10329-39. doi: 10.1158/0008-5472.CAN-10-0578. Epub 2010 Oct 22.


Therapeutic approach of primary bone tumours by bisphosphonates.

Moriceau G, Ory B, Gobin B, Verrecchia F, Gouin F, Blanchard F, Redini F, Heymann D.

Curr Pharm Des. 2010;16(27):2981-7. Review.


Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment.

Lamoureux F, Moriceau G, Picarda G, Rousseau J, Trichet V, Rédini F.

Biochim Biophys Acta. 2010 Jan;1805(1):17-24. doi: 10.1016/j.bbcan.2009.08.004. Epub 2009 Sep 3. Review.


Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells.

Ory B, Moriceau G, Trichet V, Blanchard F, Berreur M, Rédini F, Rogers M, Heymann D.

J Cell Mol Med. 2008 Jun;12(3):928-41. doi: 10.1111/j.1582-4934.2008.00141.x.


Supplemental Content

Loading ...
Support Center